Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Blood Cancer Journal(2021)10.1038/s41408-021-00546-9Source: DataRank Database

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab is a research paper published in Blood Cancer Journal (2021). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.61)OA: goldTopics (55)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Valeria Cancelli ORCID,Luisa Imberti ORCID,Kerry Dobbs ORCID,Alessandra Sottini ORCID,Chiara Pagani ORCID

Live enrichment

PubMed:34521813 PMC:PMC8438656 OpenAlex:https://openalex.org/W3199976854

Regione Lombardia

Grant: Risposta immune in pazienti con COVID-19 e co-morbidità

Division of Intramural Research of the National Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial Research

FWCI

2.61

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.nature.com/articles/s41408-021-00546-9.pdf

publisherhttps://www.nature.com/articles/s41408-021-00546-9.pdf

journalhttps://doi.org/10.1038/s41408-021-00546-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34521813

repositoryhttp://europepmc.org/pmc/articles/PMC8438656

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 and healthcare impactsAdultAgedAged, 80 and overAntibodies, ViralAntibody FormationAntibody SpecificityCOVID-19Case-Control StudiesFemaleFollow-Up StudiesHematologic NeoplasmsHospitalizationHumansImmunity, HumoralItalyLongitudinal StudiesMaleMiddle AgedRituximabSARS-CoV-2

MeSH Terms

RituximabCOVID-19SARS-CoV-2AdultAgedAged, 80 and overAntibodies, ViralAntibody FormationAntibody SpecificityFemaleFollow-Up StudiesHospitalizationHumansItalyLongitudinal StudiesMaleMiddle AgedCase-Control StudiesHematologic NeoplasmsImmunity, Humoral

Keywords

MedicineSeroconversionRituximabLymphomaInternal medicineHematologyImmunologyLymphoproliferative disordersAntibodyGastroenterologyDiffuse large B-cell lymphomaFollicular lymphoma

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients

10.6084/m9.figshare.26667568.v1figshare

Additional file 1 of IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients

10.6084/m9.figshare.26667568figshare

Additional file 2 of IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients

10.6084/m9.figshare.26667571.v1figshare

Additional file 2 of IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients

10.6084/m9.figshare.26667571figshare